Regular laboratory monitoring typically includes HbA1c every 3 months, lipid panels, kidney function tests, and liver enzymes as clinically indicated
These results suggest that for patients already receiving a GLP-1 RA who require additional treatment for glycaemic control, a switch to semaglutide could provide HbA1c and weight benefits without the need for more frequent administration
Medication is sourced exclusively from FDA-registered, licensed pharmacies through a LegitScript certified practice
Our team will provide you with aftercare instructions and discuss any possible side effects, such as mild redness or tenderness at the injection site, which typically resolve quickly on their own
Semaglutide, retailed as Ozempic and Wegovy, is a GLP- 1 receptor agonist
The glucagon receptor influences energy balance and fat metabolism